Meda is broadening its collaboration with the Indian pharmaceutical company Cipla, thereby expanding its exclusive rights to Dymista and future product development. Through the extended partnership, Meda now have full coverage in all growth markets in Latin- and South America, Middle East and Africa and Asia, including more than 120 new markets.
Meda and Cipla will cooperate on product development of Dymista. Cipla will be responsible for formulation, while Meda will be responsible for clinical development, registration, marketing and sales. The companies will also collaborate on future production of Dymista and any new products developed.
“Through this expanded partnership, we secure opportunities for global commercialization of Dymista and optimize future product development,” says Anders Lönner, Meda’s CEO. “Not least, we see great potential in several priority growth markets such as China.”
Dymista is a novel nasal treatment of allergic rhinitis. The efficacy and...